The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide

Current Medical Research and Opinion

Volumn 18, Issue 2, 2002, Pages 59-63

  Achimastos, Apostolos ^a   Liberopoulos, Evagelos ^a   Nikas, Spyros ^a   Bairaktari, Eleni ^a   Miltiadous, George ^a   Tsimihodimos, Vasilios ^a   Elisaf, Moses ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Combination therapy; Hyperuricaemia; Indapamide; Micronised fenofibrate; Uricosuria

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDAPAMIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG RESPONSE; DYSLIPIDEMIA; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPERURICEMIA; MALE; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; APOLIPOPROTEINS B; CHOLESTEROL; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOGEN; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INDAPAMIDE; MALE; MIDDLE AGED; PROCETOFEN; TRIGLYCERIDES; URIC ACID;

EID: 0036244718     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079902125000273     Document Type: Article

References (19)

1. Indapamide. Effects on apoprotein, lipoprotein and glucoregulation in ambulatory diabetic patients
2. The pharmacology and clinical pharmacology of indapamide
3. Effectiveness and metabolic effects of perindopril and diuretics combination in primary hypertension
4. The effects of the addition of losartan on uric acid metabolism in patients receiving indapamide
5. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance and plasma uric acid concentration
6. Hypertriglyceridemia and hyperuricemia: Effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind placebo controlled trial
7. Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia
8. Effect of fenofibrate on serum uric acid levels
9. Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: Case histories
10. Plasma and Lp(a) associated PAF-acetylhydrolase activity in uremic patients undergoing dialysis procedures
11. Estimation of LDL cholesterol based on Friedewald formula and on ApoB levels
12. Comparison of the efficacy of atorvastatin and micronised fenofibrate in the treatment of mixed hyperlipidemia
13. The physiological basis and clinical uses of diuretics
14. Treatment of dyslipidaemias in patients with established vascular disease: A revival of the fibrates
15. Micronized fenofibrate: A review of its pharmacodynamic properties and clinical efficasy in the management of dyslipidemia
16. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa and IIb hyperlipidemia
17. Effect of three fibrate derivatives and two HMG-CoA reductase inhibitors on plasma fibrinogen levels in patients with primary hypercholesterolemia
18. Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemia
19. The glucose fatty-acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus